Modality
ADC
MOA
HER2
Target
CGRP
Pathway
RAS/MAPK
ThymomaOCD
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
~Oct 2021
→ ~Jan 2023
Phase 3
Apr 2023
→ Aug 2026
Phase 3Current
NCT03648944
1,187 pts·OCD
2025-12→TBD·Recruiting
NCT03654689
534 pts·OCD
2023-04→TBD·Not yet recruiting
NCT06357902
1,557 pts·Thymoma
2023-07→2026-08·Active
3,278 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-205mo awayPh3 Readout· Thymoma
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P3
Not yet…
P3
Active
P3
Recruit…
Catalysts
Ph3 Readout
2026-08-20 · 5mo away
Thymoma
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03648944 | Phase 3 | OCD | Recruiting | 1187 | ACR20 |
| NCT03654689 | Phase 3 | OCD | Not yet recr... | 534 | VA |
| NCT06357902 | Phase 3 | Thymoma | Active | 1557 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP | |
| MDG-611 | Madrigal Pharma | Approved | CGRP |